Company to present Tuesday, January 13th at 10:00 a.m. PT / 1:00 p.m. ET GAITHERSBURG, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced its participation in the inaugural Global BioInnovation Forum, taking place virtually during the JP Morgan Healthcare Conference on January 13, 2026. Elutia will highlight progress in its NXT-41x program, a next-generation antibiotic-eluting biomatrix for use in p ...

Core Insights - Elutia Inc. is advancing its NXT-41x biomatrix technology to address a significant unmet medical need in plastic and reconstructive surgery, targeting a market opportunity estimated at $1.5 billion in the U.S. [1][5] Business Highlights - The CEO emphasized the importance of addressing infection in breast reconstruction, which affects 15-20% of cases, and highlighted the company's antibiotic-eluting technology aimed at preventing such infections [4]. - Elutia sold its BioEnvelope business to Boston Scientific for $88 million, with proceeds allocated to eliminate debt and fund the NXT-41x development program [5]. - The company is progressing with the NXT-41x biomatrix, which is expected to receive FDA clearance for the base matrix in the second half of 2026 and for the drug-eluting version in the first half of 2027 [5]. - Elutia's balance sheet has been strengthened through the sale of the BioEnvelope business, allowing for the full funding of the NXT-41x platform development without shareholder dilution [5]. - Guido J. Neels has been appointed to the Board of Directors, bringing experience from his previous role as COO of Guidant Corporation [5]. Financial Results - For Q3 2025, Elutia reported net sales of $3.3 million, a decrease from $3.7 million in Q3 2024, with SimpliDerm sales at $2.4 million and cardiovascular products at $0.9 million [6]. - The gross margin on a GAAP basis improved to 55.8% from 48.9% year-over-year, while the adjusted gross margin rose to 63.9% from 56.3% [6][20]. - Total operating expenses decreased to $7.1 million from $11.0 million, resulting in a loss from operations of $5.2 million, down from $9.2 million in the prior year [6]. - The net loss from continuing operations was $0.4 million, compared to a net income of $3.3 million in Q3 2024 [6]. - As of September 30, 2025, the cash balance was $4.7 million, bolstered by $80.3 million received from the BioEnvelope business sale [7]. Market Opportunity - The NXT-41x biomatrix is positioned to tackle serious complications faced by one in three patients undergoing breast reconstruction, addressing a critical need in the $1.5 billion U.S. market [5].

Core Insights - Elutia Inc. has been recognized with two awards in the 2025 Medical Device Network Excellence Awards for its innovations in drug-eluting biomatrix technologies and the successful launch of EluPro [3][4] - EluPro has shown strong commercial performance since its pilot launch in September 2024, with a sequential sales increase of 84% in Q1 2025 and a year-over-year revenue increase of 31% in BioEnvelope sales [4][6] - The product is cleared for use with all major cardiac implantable electronic devices (CIEDs) and neurostimulation devices, addressing complications such as infection and migration [5][6] Company Performance - EluPro was commercially launched in January 2025 and has received approvals from 150 hospital value analysis committees, indicating strong clinical demand [4][6] - The product has established partnerships with seven major group purchasing organizations, reflecting its acceptance within the healthcare procurement ecosystem [4] Product Details - EluPro combines a soft, regenerative biomatrix with antibiotics rifampin and minocycline to enhance healing and reduce complications associated with CIEDs [5][6] - With over 600,000 CIEDs implanted annually in the U.S. and complications occurring in 5-7% of cases, EluPro aims to improve patient outcomes significantly [6] Industry Recognition - The Medical Device Network Excellence Awards analyze over 1 billion datasets annually to recognize top-tier companies in the medical device industry [8] - The awards honor innovative companies that drive positive change, highlighting Elutia's commitment to advancing medical technology [8]